Nutraceutical Composition for Spike Protein Blocking and Cytokine Control

The patent introduces nutraceutical compounds as intermediary substances that bind to spike proteins and prevent their attachment to ACE2 receptors. These compounds act as mediators between the spike proteins and cell receptors, blocking the harmful interaction while allowing the immune system to respond safely to the vaccine or infection.

The patent applies preliminary protective measures by administering nutraceutical compounds before spike proteins can attach to and penetrate cell membranes. This pre-emptive action creates a protective barrier that prevents the harmful effects of cytokine storms and inflammation before they can develop.

The patent combines multiple nutraceutical compounds with different mechanisms of action into a unified treatment regimen. This merging of compounds creates synergistic effects where the combined inhibition efficacy exceeds the sum of individual activities, simultaneously blocking attachment, penetration, and replication of spike proteins.

The patent creates a composite nutraceutical formulation where multiple compounds work together as an integrated system. Each compound contributes specific antiviral properties, and their combination produces enhanced therapeutic effects that address multiple stages of viral pathogenesis simultaneously.

The patent implements preliminary protective measures that address both acute and long-term concerns simultaneously. By blocking spike protein attachment and penetration from the outset, the treatment prevents the development of long-term health issues while also managing acute symptoms, rather than treating only after damage occurs.

The patent establishes continuous protective action that extends beyond acute symptom resolution. The nutraceutical compounds maintain ongoing inhibition of spike protein activities and inflammatory responses, preventing the transition from acute to chronic health issues and ensuring sustained therapeutic benefit.